Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

First International Summit on Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

May

Today In Oncology

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Related Videos

Deborah Collyar: What's In It for Patients?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults

Whole-Genome Sequencing Test Enables Genomically Informed Treatment Decision-Making in Multiple Myeloma

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Noninvasive Urine Test May Provide Grade Group Information in Patients With Prostate Cancer